← Back to patent-cliff list
依非韦伦/拉米夫定/富马酸替诺福韦二吡呋酯
Tier C — Watch / tradeEfavirenz/Lamivudine/Tenofovir Disoproxil Fumarate
Mylan Nv
Originator
2018
First approval
-
Expiry (public)
No sales data
Peak sales
化学药
Type
Targets：RT、HIV-1 RT、HBV pol
Brand：Symfi
Indications (approved)：HIV感染
Regional status
US
撤市
EU
-
China
批准上市
2022-11-30
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Efavirenz/Lamivudine/Tenofovir Disoproxil Fumarate?
Approved indications include: HIV感染.
When does the Efavirenz/Lamivudine/Tenofovir Disoproxil Fumarate patent expire?
No public expiry year is available for Efavirenz/Lamivudine/Tenofovir Disoproxil Fumarate yet; this page updates once verified.
How do I get a quote for Efavirenz/Lamivudine/Tenofovir Disoproxil Fumarate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24